CoChat

The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element

Open access
Prieur, Xavier, Coste, Hervé, Rodríguez, Joan C. · 2003 · Journal of Biological Chemistry

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

The newly identified apolipoprotein AV (apoAV) gene is a key player in determining plasma triglyceride concentrations. Because hypertriglyceridemia is a major independent risk factor in coronary artery disease, the understanding of the regulation of the expression of this gene is of considerable importance. We presently characterize the structure, the transcription start site, and the promoter of the human apoAV gene. Since the peroxisome proliferator-activated receptor-alpha (PPARalpha) and the farnesoid X-activated receptor (FXR) have been shown to modulate the expression of genes involved in triglyceride metabolism, we evaluated the potential role of these nuclear receptors in the regulation of apoAV transcription. Bile acids and FXR induced the apoAV gene promoter activity. 5'-Deletion, mutagenesis, and gel shift analysis identified a heretofore unknown element at positions -103/-84 consisting of an inverted repeat of two consensus receptor-binding hexads separated by 8 nucleotides (IR8), which was required for the response to bile acid-activated FXR. The isolated IR8 element conferred FXR responsiveness on a heterologous promoter. On the other hand, in apoAV-expressing human hepatic Hep3B cells, transfection of PPARalpha specifically enhanced apoAV promoter activity. By deletion, site-directed mutagenesis, and binding analysis, a PPARalpha response element located 271 bp upstream of the transcription start site was identified. Finally, treatment with a specific PPARalpha activator led to a significant induction of apoAV mRNA expression in hepatocytes. The identification of apoAV as a PPARalpha target gene has major implications with respect to mechanisms whereby pharmacological PPARalpha agonists may exert their beneficial hypotriglyceridemic actions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.m301302200

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
FIG. 2 Transactivation of the human apoAV gene promoter by PPAR 𝛂 . Hep3B cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5 ′ -flanking region ( -617/ + 18) of the human apoAV gene or the empty pGL3-basic vector along with a plasmid expressing human PPAR 𝛂 or the empty vector pSG5 as control. Cells were treated with vehicle alone or 1 𝛍 M GW9003 for 48 h, and luciferase activities were measured and expressed as described under 'Experimental Procedures.' *, p < 0.001 versus control.
FIG. 2 Transactivation of the human apoAV gene promoter by PPAR 𝛂 . Hep3B cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5 ′ -flanking region ( -617/ + 18) of the human apoAV gene or the empty pGL3-basic vector along with a plasmid expressing human PPAR 𝛂 or the empty vector pSG5 as control. Cells were treated with vehicle alone or 1 𝛍 M GW9003 for 48 h, and luciferase activities were measured and expressed as described under 'Experimental Procedures.' *, p < 0.001 versus control.CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
FIG. 5 PPAR 𝛂 -RXR 𝛂 heterodimers can specifically bind to the DR1 element of the human apoAV promoter. A , EMSAs were performed using in vitro transcribed/translated human PPAR 𝛂 (2.5 𝛍 l), human RXR 𝛂 (2.5 𝛍 l), or unprogrammed reticulocyte lysate ( -), when indicated, and labeled double-stranded oligonucleotides corresponding to the indicated fragments of the human apoAV gene promoter as described under 'Experimental Procedures.' The lysate volumes were kept constant by the addition of unprogrammed lysate. CONTROL , a labeled probe that contains the PPRE of the mitHMGS gene (3-fold less was used). B , competition experiments for binding of PPAR 𝛂 -RXR 𝛂 heterodimers to the labeled double-stranded oligonucleotides corresponding to nt -275 to -247 ( AvDR1 ) were performed by adding a 10-, 50-, and 250-fold molar excess of the indicated unlabeled probes. mtAvDR1 is a modified version of wtAvDR1 with mutations corresponding to nt -263G 3 C/ -262G 3 A/ -261T 3 A. The specific PPAR 𝛂 -RXR 𝛂 -PPRE complex is indicated by an arrow . CONT , PPRE of mitHMGS gene (48); wt , wild type; mt , mutated.
FIG. 5 PPAR 𝛂 -RXR 𝛂 heterodimers can specifically bind to the DR1 element of the human apoAV promoter. A , EMSAs were performed using in vitro transcribed/translated human PPAR 𝛂 (2.5 𝛍 l), human RXR 𝛂 (2.5 𝛍 l), or unprogrammed reticulocyte lysate ( -), when indicated, and labeled double-stranded oligonucleotides corresponding to the indicated fragments of the human apoAV gene promoter as described under 'Experimental Procedures.' The lysate volumes were kept constant by the addition of unprogrammed lysate. CONTROL , a labeled probe that contains the PPRE of the mitHMGS gene (3-fold less was used). B , competition experiments for binding of PPAR 𝛂 -RXR 𝛂 heterodimers to the labeled double-stranded oligonucleotides corresponding to nt -275 to -247 ( AvDR1 ) were performed by adding a 10-, 50-, and 250-fold molar excess of the indicated unlabeled probes. mtAvDR1 is a modified version of wtAvDR1 with mutations corresponding to nt -263G 3 C/ -262G 3 A/ -261T 3 A. The specific PPAR 𝛂 -RXR 𝛂 -PPRE complex is indicated by an arrow . CONT , PPRE of mitHMGS gene (48); wt , wild type; mt , mutated.CC-BY · From the PDF
FIG. 6 PPAR 𝛂 agonists enhance apoAV mRNA levels in human HepG2 cells and primary cynomolgus hepatocytes. Hepatocytes isolated from cynomolgus liver ( Cyno ) and human hepatoma HepG2 cells were treated for 48h with vehicle ( Control ) or 1 𝛍 M GW9003. Total RNA was extracted for analysis by real time RT-PCR as described under 'Experimental Procedures.' Specific apoAV mRNA levels normalized to 18 S content are expressed relative to untreated cells set as 100 (mean ± S.D.). *, p < 0.01 versus control.
FIG. 6 PPAR 𝛂 agonists enhance apoAV mRNA levels in human HepG2 cells and primary cynomolgus hepatocytes. Hepatocytes isolated from cynomolgus liver ( Cyno ) and human hepatoma HepG2 cells were treated for 48h with vehicle ( Control ) or 1 𝛍 M GW9003. Total RNA was extracted for analysis by real time RT-PCR as described under 'Experimental Procedures.' Specific apoAV mRNA levels normalized to 18 S content are expressed relative to untreated cells set as 100 (mean ± S.D.). *, p < 0.01 versus control.CC-BY · From the PDF
FIG. 7 Bile acids induce human apoAV promoter activity via FXR. Hep3B ( A and C ) and CV-1 ( B ) cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5 ′ -flanking region ( -617/ + 18) of the human apoAV gene or the empty pGL3-basic vector along with a plasmid expressing human FXR or the empty vector pSG5 as control. Cells were treated for 48 h with vehicle alone, with increasing concentrations of CDCA ( A and B ), or with 1 𝛍 M GW4064 ( C ), and luciferase activities were measured and expressed as described under 'Experimental Procedures.' Significant differences compared with the corresponding pSG5 control are as follows: *, p < 0.005; **, p < 0.001; #, p < 0.0005.
FIG. 7 Bile acids induce human apoAV promoter activity via FXR. Hep3B ( A and C ) and CV-1 ( B ) cells were transfected with a plasmid containing a luciferase reporter gene driven by the 5 ′ -flanking region ( -617/ + 18) of the human apoAV gene or the empty pGL3-basic vector along with a plasmid expressing human FXR or the empty vector pSG5 as control. Cells were treated for 48 h with vehicle alone, with increasing concentrations of CDCA ( A and B ), or with 1 𝛍 M GW4064 ( C ), and luciferase activities were measured and expressed as described under 'Experimental Procedures.' Significant differences compared with the corresponding pSG5 control are as follows: *, p < 0.005; **, p < 0.001; #, p < 0.0005.CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Image 9
CC-BY · From the PDF
FIG. 8 The region between nt H11546 242 and H11546 82 of the human apoAV promoter mediates the response to bile acid-activated FXR. CV-1 cells were cotransfected with reporter plasmids containing the firefly luciferase gene driven by progressively 5 ′ -shortened fragments of the apoAV promoter together with the empty vector pSG5 or a plasmid expressing human FXR. Cells were treated with vehicle or 100 𝛍 M CDCA for 48 h, and luciferase activities were measured as described under 'Experimental Procedures.' Results are expressed as -fold induction over control. LUC , luciferase.
FIG. 8 The region between nt H11546 242 and H11546 82 of the human apoAV promoter mediates the response to bile acid-activated FXR. CV-1 cells were cotransfected with reporter plasmids containing the firefly luciferase gene driven by progressively 5 ′ -shortened fragments of the apoAV promoter together with the empty vector pSG5 or a plasmid expressing human FXR. Cells were treated with vehicle or 100 𝛍 M CDCA for 48 h, and luciferase activities were measured as described under 'Experimental Procedures.' Results are expressed as -fold induction over control. LUC , luciferase.CC-BY · From the PDF
FIG. 9 Mutation of the IR8 element on the human apoAV promoter eliminates the response to FXR. A , human apoAV gene promoter sequence surrounding the IR8 element. The g ray box denotes the IR8 sequence. The AGGTCA half-sites are indicated by horizontal arrows . The wild-type nucleotides that were modified by site-directed mutagenesis are underlined . The corresponding mutated nucleotides are shown below the vertical arrows and within the gray squares . B and C , Hep3B cells were transfected with a plasmid expressing human FXR or the empty pSG5 vector as control together with reporter constructs containing the wild-type or site-directed mutated 5 ′ -flanking regions of the human apoAV gene or the empty pGL3-basic vector as negative control. Cells were treated for 48 h with vehicle, 100 𝛍 M CDCA, or 1 𝛍 M GW4064, and luciferase activities were measured and expressed as described under 'Experimental Procedures.' Significant differences compared with the corresponding pSG5 control are as follows: *, p < 0.001; **, p < 0.0005. The crosses depict the presence of site-directed mutations in the IR8 element. LUC , luciferase.
FIG. 9 Mutation of the IR8 element on the human apoAV promoter eliminates the response to FXR. A , human apoAV gene promoter sequence surrounding the IR8 element. The g ray box denotes the IR8 sequence. The AGGTCA half-sites are indicated by horizontal arrows . The wild-type nucleotides that were modified by site-directed mutagenesis are underlined . The corresponding mutated nucleotides are shown below the vertical arrows and within the gray squares . B and C , Hep3B cells were transfected with a plasmid expressing human FXR or the empty pSG5 vector as control together with reporter constructs containing the wild-type or site-directed mutated 5 ′ -flanking regions of the human apoAV gene or the empty pGL3-basic vector as negative control. Cells were treated for 48 h with vehicle, 100 𝛍 M CDCA, or 1 𝛍 M GW4064, and luciferase activities were measured and expressed as described under 'Experimental Procedures.' Significant differences compared with the corresponding pSG5 control are as follows: *, p < 0.001; **, p < 0.0005. The crosses depict the presence of site-directed mutations in the IR8 element. LUC , luciferase.CC-BY · From the PDF
Image 12
CC-BY · From the PDF
Image 13
CC-BY · From the PDF
Image 14
CC-BY · From the PDF
FIG. 10 The IR8 element present in the promoter of the human apoAV gene (AvIR8) confers FXR responsiveness to heterologous promoters. A , the apoAV IR8 element confers transactivation by bile acid-activated FXR in a copy number-dependent manner. Hep3B cells were transiently transfected with plasmids expressing human FXR or the empty pSG5 vector as control, together with reporter constructs containing 1-4 copies of the sequence corresponding to nt -109 to -80 ( AvIR8 ) of the human apoAV gene promoter or four copies of the ER8 element present in the MRP2 gene promoter ( ER8 ) cloned in front of a heterologous TK promoter-driven luciferase. The empty pGL3-TK reporter vector was used as negative control. Cells were treated with vehicle or 100 𝛍 M CDCA for 48 h, and luciferase activities were measured as described under 'Experimental Procedures.' Results are expressed as -fold induction over control. B , human apoAV gene promoter sequence surrounding the IR8 element and mutated versions used in C . The hexameric consensus sites are in boldface type , and their orientations are indicated by arrows . Mutations in half-sites are shown in lowercase type and within gray squares . C , functional effects of mutations on hexameric consensus sites. Experiments were performed as in A with reporter constructs containing four copies of the wild-type ( wt ) ( wtAvIR8 ) or mutant ( mt1AvIR8 , mt2AvIR8 , mt3AvIR8 ) sequences corresponding to nt -109 to -80 of the human apoAV gene promoter cloned in front of TK promoter-driven luciferase.
FIG. 10 The IR8 element present in the promoter of the human apoAV gene (AvIR8) confers FXR responsiveness to heterologous promoters. A , the apoAV IR8 element confers transactivation by bile acid-activated FXR in a copy number-dependent manner. Hep3B cells were transiently transfected with plasmids expressing human FXR or the empty pSG5 vector as control, together with reporter constructs containing 1-4 copies of the sequence corresponding to nt -109 to -80 ( AvIR8 ) of the human apoAV gene promoter or four copies of the ER8 element present in the MRP2 gene promoter ( ER8 ) cloned in front of a heterologous TK promoter-driven luciferase. The empty pGL3-TK reporter vector was used as negative control. Cells were treated with vehicle or 100 𝛍 M CDCA for 48 h, and luciferase activities were measured as described under 'Experimental Procedures.' Results are expressed as -fold induction over control. B , human apoAV gene promoter sequence surrounding the IR8 element and mutated versions used in C . The hexameric consensus sites are in boldface type , and their orientations are indicated by arrows . Mutations in half-sites are shown in lowercase type and within gray squares . C , functional effects of mutations on hexameric consensus sites. Experiments were performed as in A with reporter constructs containing four copies of the wild-type ( wt ) ( wtAvIR8 ) or mutant ( mt1AvIR8 , mt2AvIR8 , mt3AvIR8 ) sequences corresponding to nt -109 to -80 of the human apoAV gene promoter cloned in front of TK promoter-driven luciferase.CC-BY · From the PDF
Image 16
CC-BY · From the PDF
Image 17
CC-BY · From the PDF
FIG. 12 apoAV mRNA levels are not induced by treatments with an FXR agonist or a bile acid. Hepatocytes isolated from cynomolgus liver ( Cyno ) and human hepatoma HepG2 cells were treated for 48 h with vehicle ( Control ), 1 𝛍 M GW4064 or 30 𝛍 M LCA. Total RNA was extracted for analysis by real time RT-PCR as described under 'Experimental Procedures.' Specific mRNA levels normalized to 18 S content are expressed relative to untreated cells set as 100 for each gene (mean ± S.D.). Significant differences compared with the untreated control are as follows: *, p < 0.005; #, p < 0.01; **, p < 0.0001.
FIG. 12 apoAV mRNA levels are not induced by treatments with an FXR agonist or a bile acid. Hepatocytes isolated from cynomolgus liver ( Cyno ) and human hepatoma HepG2 cells were treated for 48 h with vehicle ( Control ), 1 𝛍 M GW4064 or 30 𝛍 M LCA. Total RNA was extracted for analysis by real time RT-PCR as described under 'Experimental Procedures.' Specific mRNA levels normalized to 18 S content are expressed relative to untreated cells set as 100 for each gene (mean ± S.D.). Significant differences compared with the untreated control are as follows: *, p < 0.005; #, p < 0.01; **, p < 0.0001.CC-BY · From the PDF
Image 19
CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Desvergne, 1999, Endocr. Rev., 20, 649
  2. Applied Biosystems (2001) User Bulletin 2, Foster City, CA

Cited by

See all 200

Metadata

Authors
Prieur, X., Coste, H., & Rodríguez, J. C.
Affiliations
GlaxoSmithKline (France) (FR)
Corresponding author
Rodríguez, Joan C.
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
2003-07
Volume
278
Issue
28
Pages
25468-25480
ISSN
0021-9258 (ISSN-L)
OpenAlex
W2032849264
Cited by
194
References
55
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 6
FWCI
7.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
PPARα, farnesoid X receptor, bile acids, transcriptional regulation, promoter structure, transcription start sites, hypertriglyceridemia, hepatic gene expression, PPARα agonist, hypotriglyceridemic effect, triglyceride metabolism
MeSH terms
Apolipoprotein A-V, Receptor, Farnesoid X-Activated, Apolipoproteins, Apolipoproteins A, Base Sequence, Cell Line, Cell Nucleus, Chromosome Mapping, DNA-Binding Proteins, Exons, Carcinoma, Hepatocellular, Humans, Introns, Luciferases, Models, Genetic, Molecular Sequence Data, Mutation, Plasmids, DNA Ligases, Promoter Regions, Genetic, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Protein Biosynthesis, Transcriptional Activation, Mutagenesis, Site-Directed, Gene Deletion, Receptors, Cytoplasmic and Nuclear, Receptors, Retinoic Acid, Dimerization, 5' Untranslated Regions, Reverse Transcriptase Polymerase Chain Reaction, Response Elements, Hepatocytes, Retinoid X Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.